BTIG Reiterates Buy on ArriVent BioPharma, Maintains $29 Price Target

BTIG analyst Jeet Mukherjee has reiterated a Buy rating on ArriVent BioPharma (NASDAQ: AVBP) and has maintained a price target of $29 for the stock.